M Margaret Juliana Selected Research

Body Weight (Weight, Body)

9/2017	Lack of chemopreventive efficacy of metformin in rodent models of urinary bladder, head and neck, and colon/intestine cancer.
4/2015	Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy.
5/2013	Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis.
4/2010	Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy.
4/2008	Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes.
7/2007	Preventive effects of polyphenon E on urinary bladder and mammary cancers in rats and correlations with serum and urine levels of tea polyphenols.
4/2006	Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

M Margaret Juliana Research Topics

Disease

20	Neoplasms (Cancer) 01/2020 - 02/2004
14	Breast Neoplasms (Breast Cancer) 01/2020 - 02/2004
9	Carcinogenesis 03/2015 - 04/2006
8	Urinary Bladder Neoplasms (Bladder Cancer) 09/2017 - 03/2005
7	Body Weight (Weight, Body) 09/2017 - 04/2006
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 08/2014 - 02/2010
2	Carcinoma (Carcinomatosis) 02/2009 - 11/2008
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 09/2017
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 09/2017
1	Intestinal Neoplasms (Intestinal Cancer) 07/2016
1	Head and Neck Neoplasms (Head and Neck Cancer) 07/2016
1	Actinic Keratosis 08/2014
1	Pancreatic Neoplasms (Pancreatic Cancer) 05/2013
1	Colonic Neoplasms (Colon Cancer) 05/2012
1	Neoplasm Metastasis (Metastasis) 02/2010
1	Skin Neoplasms (Skin Cancer) 11/2009
1	Aberrant Crypt Foci 11/2009
1	Adenoma (Adenomas) 11/2009
1	Hyperplasia 07/2006
1	Papilloma (Papillomatosis) 07/2006

Drug/Important Bio-Agent (IBA)

12	Methylnitrosourea (N-Methyl-N-nitrosourea)IBA 01/2020 - 02/2005
6	hydroxide ionIBA 04/2015 - 03/2005
5	Bexarotene (LGD1069)FDA Link 01/2020 - 02/2005
4	Gefitinib (Iressa)FDA Link 01/2020 - 04/2008
4	Biomarkers (Surrogate Marker)IBA 01/2020 - 04/2008
4	Naproxen (Naprosyn)FDA LinkGeneric 01/2020 - 11/2009
4	Estrogen ReceptorsIBA 01/2020 - 09/2007
4	NitrosaminesIBA 09/2017 - 11/2008
3	Metformin (Glucophage)FDA LinkGeneric 01/2020 - 03/2015
3	Glycoproteins (Glycoprotein)IBA 08/2014 - 07/2006
3	OsteopontinIBA 08/2014 - 07/2006
3	Proteins (Proteins, Gene)FDA Link 05/2011 - 07/2006
2	vorozoleIBA 01/2020 - 04/2008
2	Atorvastatin (Lipitor)FDA Link 01/2020 - 02/2009
2	Tamoxifen FDA LinkGeneric 01/2020 - 02/2009
2	Insulin (Novolin)FDA Link 09/2017 - 03/2015
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 04/2015 - 11/2009
2	ErbB Receptors (EGF Receptor)IBA 05/2013 - 04/2008
2	AzoxymethaneIBA 05/2012 - 11/2009
2	CarcinogensIBA 09/2011 - 03/2005
1	Pharmaceutical PreparationsIBA 01/2020
1	Progesterone Receptors (Progesterone Receptor)IBA 01/2020
1	benz(a)anthracene (benzanthracene)IBA 07/2016
1	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 07/2016
1	TriterpenesIBA 07/2016
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 04/2015
1	Proton Pump InhibitorsIBA 04/2015
1	Omeprazole (Prilosec)FDA LinkGeneric 04/2015
1	BiguanidesIBA 03/2015
1	AMP-Activated Protein KinasesIBA 03/2015
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 05/2013
1	3,3'-diindolylmethane (diindolylmethane)IBA 09/2011
1	indole-3-carbinolIBA 09/2011
1	beta-NaphthoflavoneIBA 09/2011
1	9,10-Dimethyl-1,2-benzanthraceneIBA 09/2011
1	FlavonoidsIBA 09/2011
1	Annexin A2 (Annexin II)IBA 05/2011
1	NucleolinIBA 05/2011
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 05/2011
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2011
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 04/2010
1	ResveratrolIBA 04/2010
1	AgarIBA 02/2010
1	naproxen-n-butyl nitrateIBA 11/2009
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 02/2009
1	Lovastatin (Mevacor)FDA LinkGeneric 02/2009
1	Retinoid X Receptors (Retinoid X Receptor)IBA 02/2009
1	PPAR gammaIBA 11/2008
1	Rosiglitazone (Avandia)FDA Link 11/2008
1	PPAR-gamma AgonistsIBA 11/2008
1	Dihydrotachysterol (AT 10)IBA 04/2008
1	TeaIBA 07/2007
1	PolyphenolsIBA 07/2007
1	polyphenon EIBA 07/2007
1	DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)IBA 07/2006
1	Bromodeoxyuridine (BrdU)IBA 07/2006
1	tipifarnib (R115777)IBA 04/2006
1	TransferasesIBA 04/2006
1	Apoptosis Regulatory ProteinsIBA 03/2005
1	SurvivinIBA 03/2005
1	Indomethacin (Indometacin)FDA LinkGeneric 03/2005
1	Alitretinoin FDA Link 02/2004
1	RetinoidsIBA 02/2004
1	retinamideIBA 02/2004
1	FenretinideIBA 02/2004

Therapy/Procedure

4	Therapeutics 05/2013 - 02/2005
1	Chemoprevention 04/2015